Yinjia Bio
引加生物
Yinjia Bio (引加生物) is a Shanghai-based protein technology platform founded at the end of 2020, focused on building a high-end protein platform spanning protein selection, GMP manufacturing, and single-cell multi-functional protein analysis . The company has raised multiple rounds from institutional investors including Gaorong Ventures, which led its Pre-A round in July 2021 , and CMB International, which led its Series A of nearly RMB 100 million in early 2023 . CDH Investments and FuRong Investment also participated across rounds . Yinjia Bio has pursued partnerships with top research institutions including Johns Hopkins University to accelerate product development , and in 2024 was named as a collaborator of BioGeometry for joint development of proteins and antibody therapeutics using generative AI .
AI-generated — may contain errors, please verify.
Coverage
BioGeometry Completes Pre-A Round, Applying Generative AI to Bio-Manufacturing
Continuously optimizing a generative AI-powered protein design platform.
Medical Device/Chip Companies Close New Funding Rounds, Driving High-Quality Growth Through R&D, Commercialization, and Supply Chain | Rong Report · February
Infinite possibilities for creating a better life.
Yinjia Biotech Closes Nearly RMB 100 Million Series A Round to Accelerate Buildout of Upstream Core Protein Ingredient Synthetic Biology Platform
Staying true to our mission as "protein craftsmen."
Rongbao · July | Multiple Companies Close New Funding Rounds, Take the Lead in Their Sectors; Pinduoduo's Olympic Season Boosts Sports Consumption for All
Continue to invest in innovative companies in new consumer brands, new technologies, healthcare, and other sectors.
Yinjia Biotech Closes Pre-A Round, Advancing Its High-End Protein Platform to New Heights
Build a leading domestic "protein artisan" platform.
